CD4 and neoplasm: They reported that: (1) systemic immune activation was evident shortly after effective therapy was administered; (2) during tumor rejection/eradication, only systemic peripheral immune cells sustained their proliferation, (3) an emergent population of peripheral CD4+ T cells were significantly expanded in patients responding to immunotherapy.